MARKET

RNAC

RNAC

Cartesian
NASDAQ
19.03
+0.11
+0.58%
Closed 16:00 02/13 EST
OPEN
19.10
PREV CLOSE
18.92
HIGH
19.39
LOW
18.56
VOLUME
37.25K
TURNOVER
--
52 WEEK HIGH
41.87
52 WEEK LOW
11.67
MARKET CAP
489.55M
P/E (TTM)
-0.5036
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at RNAC last week (0203-0207)?
Weekly Report · 4d ago
Cartesian Therapeutics Announces New Employment Inducement Grants
Barchart · 02/06 06:05
GSK (GSK) Tops Q4 Earnings and Revenue Estimates
NASDAQ · 02/05 12:05
Weekly Report: what happened at RNAC last week (0127-0131)?
Weekly Report · 02/03 10:47
Promising Developments and Strategic Expansion Bolster Buy Rating for Cartesian Therapeutics
TipRanks · 01/29 06:16
Strong Outlook for Cartesian Therapeutics: FDA SPA Agreement and Positive Phase 2b Results Boost Confidence in Descartes-08
TipRanks · 01/28 11:25
Buy Rating for Cartesian Therapeutics: Promising Phase 3 Prospects for Descartes-08 in Treating Myasthenia Gravis
TipRanks · 01/28 11:05
Cartesian Therapeutics Price Target Maintained With a $41.00/Share by Needham
Dow Jones · 01/27 13:31
More
About RNAC
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Webull offers Cartesian Therapeutics Inc stock information, including NASDAQ: RNAC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RNAC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RNAC stock methods without spending real money on the virtual paper trading platform.